The Musculoskeletal New Ventures Conference meeting offers a glimpse into emerging and promising technologies that are shaping the US Spinal Hardware Market.

The Musculoskeletal New Ventures Conference (MNVC) took place on November 4-5, 2025, in Memphis, TN. This annual conference highlights new and emerging technologies focused on the orthopedics space, and this year alone had over 45 companies present. In this article, SmartTRAK highlights four spine-focused companies with novel technologies that will impact the broader US Spinal Hardware Market, which is projected to grow at a 5-year CAGR of +4.0% by 2029E, according to SmartTRAK estimates.  

The companies covered in this article are:

• ZygoFix
  Since its presentation at MNVC last year, ZygoFix has begun surgeries in the US and currently has five surgeons incorporating the zLock into their practices. The company plans to expand access in ... (read more)
  
  
• Nanohive
  Nanohive is focused on providing patient-specific interbody implants built on its proprietary soft titanium lattice platform, which has a lower modulus of elasticity than other titanium metals and is closer to ... (read more)
• Lenoss Medical
  Lenoss Medical offers a novel biological allograft implant, Osteopearl, for the VCF market, which eliminates the need for ... (read more)
  
  
• Synergy Spine Solutions
  Synergy Spine Solutions is currently participating in FDA clinical trials to bring its Synergy disc to the US market. This unique disc preserves motion and actively corrects alignment in the cervical spine due to ... (read more)

According to SmartTRAK Product Explorer, there are over 219 companies and approximately 1,150 products competing for market share in the US Spinal Hardware Market today. The MNVC meeting provided a glimpse into new and promising technologies for the US Spinal Hardware Market.

To learn more about MNVC 2025 and the companies presenting, click the button below to download the complete article by Erin Dorgan, SmartTRAK Sr Analyst, Spine & Bone Replacement.

Spinal Simplicity’s Chief Strategy Officer Neil P. Dougherty shares how the company is advancing minimally invasive solutions to enhance patient outcomes.

Neil P. Dougherty, chief strategy officer of Spinal Simplicity, discusses the company’s position in the interventional spine and pain market, what the company looks forward to in the future and how it serves patients treated by spine surgeons and interventional pain management physicians.

Click on the following video (17:18 min) to learn more. A link to download a complete transcript of the interview is also provided below.

SmartTRAK: Hi, this is Erin Dorgan with SmartTRAK. I'm here today with Neil Dougherty, chief strategy officer with Spinal Simplicity. Thanks for joining me today, Neil.

Neil P Dougherty: Glad to be here. Thanks, Erin.

You're welcome. Can you share a little bit more about what you do at Spinal Simplicity? I know, based upon your background, you've been in the interventional space for a while. How did you end up here at Spinal Simplicity?

NPD: Well, in a startup you wear a lot of hats. So I came to Spinal Simplicity first as a vice president of sales and then moved over to focus on just business development and more of an offensive role for our expansion. And as the company grew, an opportunity for promotion was there to get to my now title, chief strategy officer.

I have been in the interventional pain space for a long time. Gosh, it's about 15 years now. Started with Medtronic, doing spinal cord stimulators and intrathecal pumps--just over five years there. Then went over to Vertiflex in that startup campaign bought by Boston Scientific and only a year of integration there after that purchase.

And then how could you forget? When the whole world basically shut down during COVID, I was kind of losing my mind a little bit. I had a couple phone calls from some doctors and also Todd Moseley, the CEO of Spinal Simplicity, and founder. And I started learning more about Spinal Simplicity. I saw their main product, Minuteman. I was like, ‘This is where I need to be.’

Okay. So speaking of Minuteman, and obviously with your background, Boston Scientific recently discontinued Vertiflex Superion. Do you think that is an opportunity for Spinal Simplicity and Minuteman to explore those customers? Or how would you describe that?

NPD: I think so. I'd like to describe it as just an acceleration to where most of those customers were probably going to graduate anyway. Superion was a great idea. I mean, it wasn't even a Vertiflex idea. This is, indirect decompression has been a great studied spine idea for a long time and it certainly wasn't the first ISP out there, but the aim is ...

Click the button below to download and read the complete transcript of SmartTRAK's interview with Neil P. Dougherty, CSO of Spinal Simplicity conducted by Erin Dorgan, SmartTRAK Sr Analyst, Spine & Bone Replacement.

Alyssa Huffman, CEO of Allumin8, discussed the company and its efforts to create a new product category of therapeutic hardware in an interview with SmartTRAK on May 9, 2025, at the 2025 North American Spine Society (NASS) Biologics Interventions meeting in Chicago, Illinois. The company is focused on treating over 200 unique bone disorders and diseases, and its first product is focused on the Spinal Hardware Market.

Click on the following video (8:49 min) to learn more. A link to download a complete transcript of the interview is also provided below.

SmartTRAK: Hi, this is Erin Dorgan, senior analyst here at SmartTRAK. I'm here today with Alyssa Huffman, CEO of ALLUMIN8. Alyssa, thank you for joining me today. Can you share a little bit more about your background and your role at ALLUMIN8?

Alyssa Huffman: Absolutely, Erin. Thanks for being here. I started in the clinic, then worked in the OR, went into sales, distribution. I worked my way into an executive function and then decided I was going to bet on myself. I have 30 years of experience throughout orthopedic spine biologics regenerative therapies.

That's awesome.

AH: And computer navigation.

Well, that's quite extensive. So we're here today at the NASS Biologic Interventions for Spinal Pathologies meeting. Why are you here with ALLUMIN8? What's the purpose for ALLUMIN8 presenting?

AH: Dr. Zorica Buser, she asked me to come and talk to the researchers and physicians about how to design a product that will actually commercialize and can get funded. There's a very different issue that's going on right now where products that only are a little bit, 1% to 3%, better than what's currently available on the market. There's a plethora of those, and so we have ...

Click the button below to download the complete transcript of our interview with Allumin8 CEO Alyssa Huffman, conducted by Erin Dorgan, SmartTRAK Senior Analyst.

SmartTRAK spotlights SentryX, a clinical-stage biopharmaceutical company developing a non-opioid platform for the treatment of acute pain after surgery,​ in an interview at AAOS 2025 in San Diego. 

SentryX Co-Founder and Chief Medical Officer Jorrit-Jan (JJ) Verlaan, MD, discusses the company’s novel implantable anesthetic for spine surgery applications in an interview with SmartTRAK at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual meeting in San Diego. The hydrogel works with all types of small-molecule drugs with a release profile that can be tailored to specific clinical needs and surgical procedures.

To find out more about SentryX and its novel technology, listen to the following video. (13:37 min.) A link to download a transcript of the interview is also provided below.

Hi, I’m Kristine Jacques, a Senior Analyst with SmartTRAK Spine. We are here at the American Academy of Orthopedic Surgeons 2025. I’m sitting down with Dr. JJ Verlaan, a spine surgeon, co-founder, and Chief Medical Officer for SentryX, a Netherlands-based company developing a groundbreaking non-opioid solution for postoperative pain. First of all, Dr. Verlaan, I want to congratulate you on being one of the top four finalists inthe OrthoPitch Event at the Academy this year. It’s quite an honor.

Dr. Jorrit-Jan Verlaan: Thank you very much.

Thank you so much for sitting down with the SmartTRAK team. I’d like to start out with you telling us about your background and how the idea came about for the Hydrogel and starting SentryX.

JJV: Thank you so much. I'm a surgeon from Utrecht in the Netherlands. I've been practicing spine surgery from the moment I got board-certified. Rapidly, during work in my practice, I noticed that patients after spine surgery are all in a lot of pain. The moment that you realize that, and you actually ask the patients how much pain they have, on a scale of 0-10 they sometimes respond with a 12. I had a chat with an anesthesiologist one day in between surgeries. We were discussing what is out there right now to treat pain. The anesthesiologist, she told me, "Well, not much, really. We're still relying on opioids. Maybe we could do something with local anesthetics, but it's not working long enough at this point." That kind of sparked the idea of doing something locally to treat the pain, but differently. Soon after, I hit upon the idea that we're developing right now in the company.

How far along are you in the development?

JJV: We started in 2017, together with my partner Bas Oosterman who is the CEO of the company. First it was just a raw idea. We soon found out that this idea, it had never been done before. That gave us the opportunity to actually file IP on our solution and go for it. At the end of 2017  we officially founded the company. We got our first employees and collaborated with a renowned institute on biofabrication. We developed a new ...

Click the button below to download and read the complete transcript of SmartTRAK's interview with SentryX Co-Founder and CMO Jorrit-Jan (JJ) Verlaan, MD, conducted by Kris Jacques, SmartTRAK Sr Analyst.